- Home
- SMTK vs CODX Comparison
SMTK vs CODX Comparison
Compare SMTK & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTK
- CODX
- Stock Information
- Founded
- SMTK 2009
- CODX 2013
- Country
- SMTK United Kingdom
- CODX United States
- Employees
- SMTK N/A
- CODX N/A
- Industry
- SMTK
- CODX Medical/Dental Instruments
- Sector
- SMTK
- CODX Health Care
- Exchange
- SMTK NYSE
- CODX Nasdaq
- Market Cap
- SMTK 13.3M
- CODX 11.9M
- IPO Year
- SMTK N/A
- CODX 2017
- Fundamental
- Price
- SMTK $1.34
- CODX $0.30
- Analyst Decision
- SMTK
- CODX Buy
- Analyst Count
- SMTK 0
- CODX 2
- Target Price
- SMTK N/A
- CODX $5.50
- AVG Volume (30 Days)
- SMTK 98.3K
- CODX 719.9K
- Earning Date
- SMTK 05-13-2025
- CODX 05-08-2025
- Dividend Yield
- SMTK N/A
- CODX N/A
- EPS Growth
- SMTK N/A
- CODX N/A
- EPS
- SMTK N/A
- CODX N/A
- Revenue
- SMTK $105,000.00
- CODX $3,497,583.00
- Revenue This Year
- SMTK N/A
- CODX N/A
- Revenue Next Year
- SMTK N/A
- CODX $42.11
- P/E Ratio
- SMTK N/A
- CODX N/A
- Revenue Growth
- SMTK 854.54
- CODX N/A
- 52 Week Low
- SMTK $1.00
- CODX $0.23
- 52 Week High
- SMTK $8.16
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- SMTK N/A
- CODX 48.86
- Support Level
- SMTK N/A
- CODX $0.23
- Resistance Level
- SMTK N/A
- CODX $0.32
- Average True Range (ATR)
- SMTK 0.00
- CODX 0.04
- MACD
- SMTK 0.00
- CODX 0.01
- Stochastic Oscillator
- SMTK 0.00
- CODX 67.38
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in a number of applications including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.